Importantly, preclinical studies underscore the significance of considering the molecular subtypes of glioblastoma when assessing the efficacy of mTOR inhibitors, as specific subtypes may exhibit better responses to mTOR inhibition, thus emphasizing the potential for personalized treatment approaches. The gene discussed is MTOR; the disease is glioblastoma.